National Cancer Institute Genome-Wide Association Study of Renal Cell Carcinoma

The National Cancer Institute (NCI) genome-wide association study (GWAS) of renal cell carcinoma (RCC) was conducted to investigate common genetic variants associated with RCC risk. The GWAS includes 1,453 RCC cases and 3,531 controls of European background from 4 studies (3 cohort, 1 case-control), scanned using the Illumina InfiniumHumanHap 550, 610 and 660W chips. This project was supported by the Intramural Research Program of the National Institutes of Health and NCI.

Data from this GWAS were pooled with those from another GWAS of RCC (2,639 cases and 5,392 controls) conducted in Europe by the International Agency for Research on Cancer and the Centre National de Gènotypage. Findings from this collaboration are described in an upcoming report (Purdue et al. Nature Genetics 2011;43(1):60-65; PMID: 21131975).

Only data from the NCI scan are included in this dbGaP submission.

• Study Design:
  • Case-Control
• Study Type:
  • Cohort
  • Case-Control
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 4735
• Subject Sample Telemetry Report (SSTR)

• BioProject
• PubMed
• BioSample
• MeSH
• PMC

Inclusion criteria:

• Non-Hispanic Caucasian race
• Adequate consent for GWAS
• Cases: diagnosis of pathologically confirmed renal cancer (International Classification of Diseases for Oncology, Second Edition, Topography C64).

Of the 4 studies participating in the NCI GWAS of RCC, 3 are prospective cohorts and 1 is a case-control study. The studies are:

Cohorts:
Alpha-Tocopherol and Beta-Carotene Cancer Prevention Study (ATBC)
American Cancer Society Cancer Prevention Study-II (CPS-II)
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)

Case-control:
National Cancer Institute United States Kidney Cancer Study (USKC)

• Primary Phenotype: Carcinoma, Renal Cell
• Kidney Neoplasms

• Principal Investigator
  • Mark Purdue. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MD, USA.
• Study Representatives
  • Demetrius Albanes. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MD, USA.
  • Wong-Ho Chow. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MD, USA.
  • Victoria Stevens. Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
• Genomics
  • Stephen Chanock. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MD, USA.
  • Kevin Jacobs. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MD, USA.
• Coordination
  • Nathaniel Rothman. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MD, USA.
  • Lee Moore. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MD, USA.
• Funding Source
  • Funding sources are listed in the acknowledgments in the supplementary section of the following publication: (In press).